文献速递消化道肿瘤放疗

老年食管癌根治性与术前放化疗的疗效与耐受性:单中心回顾性分析

Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review.
PubMed 文献 · Adv Radiat Oncol · 2020-05-21

该回顾性研究纳入1997至2019年在本中心接受根治性放疗(≥45 Gy)的≥75岁食管癌患者89例,中位年龄80岁,58%接受根治性放化疗,三分之一接受术前放化疗。术前放化疗者72%接受手术,术后90天无死亡。

要点

  • 急性3级以上毒性22%,5级毒性2%,需优化支持治疗。
  • 术前放化疗后手术者1年总生存95%,未手术者70%。

核心结论

  • 经过良好筛选的老年食管癌患者存在接受积极放疗的临床价值。
  • 需优化支持治疗、化疗方案、放疗剂量/分割及手术指征以降低毒性。

研究设计与样本

  • 单中心回顾性研究,纳入1997至2019年接受根治性放疗(≥45 Gy)的≥75岁食管癌患者89例。
  • 中位年龄80岁,78%为男性,中位校正Charlson合并症指数5(3-12),中位Karnofsky体能状态80(50-100)。

主要发现

  • 58%接受根治性放化疗,三分之一接受术前放化疗;中位处方剂量50 Gy(45-66 Gy),76%使用调强放疗。
  • 急性3级以上毒性22%,5级毒性2%。
  • 未手术者1年和2年总生存分别为70%和52%。

关键数值与推荐

  • 根治性放疗剂量≥45 Gy,中位处方剂量50 Gy(45-66 Gy)。
  • 急性3级以上毒性22%,5级毒性2%;术前放化疗后手术者1年总生存95%、2年84%。

临床怎么用

  • 对经筛选的老年食管癌患者可考虑积极放疗,但需关注支持治疗和化疗方案优化。
  • 术前放化疗后手术在老年患者中可行,术后90天无死亡。

局限性

  • 单中心回顾性研究,样本量有限(89例),结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to report outcomes of elderly patients who underwent definitive treatment involving radiation therapy for esophageal cancer at our institution. METHODS AND MATERIALS: We performed a retrospective review of patients aged ≥75 years with esophageal cancer treated with definitive radiation therapy (≥45 Gy) at our institution from 1997 to 2019. Acute and late Radiation Therapy Oncology Group grade 3+ toxicities were recorded. Survival was estimated using the Kaplan-Meier method. RESULTS: Of the 89 patients included, median age was 80 and 78% were male. Median adjusted Charlson Comorbidity Index and Karnofsky Performance Status were 5 (3-12) and 80 (50-100), respectively. The majority of cancers were adenocarcinoma (58%), distal (67%), and stage III (62%). Fifty-eight percent underwent definitive chemoradiotherapy, and one-third underwent preoperative intent chemoradiotherapy. Median prescribed dose was 50 Gy (45-66 Gy), and intensity modulated radiation therapy was used in 76%. Eighty-five percent completed the radiation therapy course. Among these, 20% had radiation therapy breaks. For those receiving concurrent chemotherapy, 37% had a dose reduction and 39.5% had a break/cycle reduction. Acute grade 3+ toxicity was 22%, with 2% grade 5 toxicity. Twenty-one of the 29 patients (72%) treated with preoperative intent underwent surgery. There were no deaths 90 days postoperatively. For patients who underwent surgery, 1- and 2-year overall survival were 95% and 84%. For those who did not undergo surgery, 1- and 2-year overall survival were 70% and 52%. CONCLUSIONS: There is a role for aggressive radiation therapy in well-selected elderly patients with esophageal cancer. However, optimization of supportive care, chemotherapy regimens, radiation therapy dose/fractionation, and surgical indications are needed to reduce toxicity.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Rahimy E, Koong A, Toesca D, et al. Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review. Adv Radiat Oncol. 2020. PMID: 33305080. doi:10.1016/j.adro.2020.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。